文献速递乳腺癌放疗

HER2阳性乳腺癌乳房切除术后放疗:HERA试验分析

Post-Mastectomy Radiation Therapy in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients: Analysis of the HERA Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-10-22

该研究基于HERA III期随机试验中1633例接受乳房切除和辅助曲妥珠单抗治疗的HER2阳性早期乳腺癌患者的前瞻性数据进行回顾性分析。结论支持对1-3枚阳性淋巴结的HER2阳性乳腺癌患者行PMRT。

核心结论

  • HER2阳性乳腺癌伴1-3枚阳性淋巴结患者接受PMRT可降低局部区域复发风险。
  • PMRT的获益幅度低于历史研究,但研究结果支持对该人群行PMRT。
  • N0患者接受PMRT未显示局部区域复发获益。

研究设计与样本

  • 本研究为对HERA III期随机临床试验前瞻性数据的回顾性分析。
  • 纳入1633例接受乳房切除和辅助曲妥珠单抗治疗的HER2阳性早期乳腺癌患者。
  • 940例(57.6%)接受PMRT,693例(42.4%)未接受PMRT。
  • 主要目标为确定PMRT对局部区域复发率的影响,采用Cox模型估计风险比,Kaplan-Meier法生成LRR曲线。

主要发现

  • PMRT组患者具有更差预后特征的疾病。

临床怎么用

  • 对于HER2阳性乳腺癌伴1-3枚阳性淋巴结且接受曲妥珠单抗治疗的患者,可考虑行PMRT以降低局部区域复发风险。
  • N0的HER2阳性乳腺癌患者行PMRT的局部区域复发获益不显著,决策需综合评估。

局限性

  • 本研究为回顾性分析,PMRT组患者具有更差预后特征的疾病,可能存在选择偏倚。
  • 未来需进一步研究确定哪些HER2阳性乳腺癌患者从PMRT中获益最大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Postmastectomy radiation therapy (PMRT) improves recurrence rates and overall survival in breast cancer patients. However, it remains unclear whether these findings can be applied to human epidermal growth factor receptor 2 (HER-2) positive patients treated with trastuzumab. METHODS AND MATERIALS: The Herceptin Adjuvant (HERA) trial is a phase III randomized clinical trial that established the efficacy of trastuzumab in HER-2 positive early stage breast cancer. The present study is a retrospective analysis of prospective data of 1633 trial patients treated with mastectomy and adjuvant trastuzumab. The primary objective of the study was to determine the effect of PMRT on loco-regional recurrence rates (LRR). Hazard ratios were estimated from Cox models, and LRR curves were generated by the Kaplan-Meier method. RESULTS: Our analysis included 940 patients (57.6%) who received PMRT and 693 patients (42.4%) who did not. Patients in the PMRT group had worse prognostic disease characteristics. At a median follow-up of 11 years, no significant difference in LRR was noted after PMRT in node negative (N0) patients (P = .96). Patients with 1 to 3 positive lymph nodes had a LRR-free survival of 97% in the PMRT group compared with 90% in the no PMRT group (hazard ratio = 0.28, P = .004) and a nonsignificant improved overall survival after PMRT (hazard ratio = 0.63, P = .06). CONCLUSIONS: PMRT delivery in HER-2 positive breast cancer patients with 1 to 3 positive lymph nodes decreases the risk of LRR. Although the magnitude of PMRT benefit is lower than historic studies, the present findings are in favor of PMRT for HER-2 positive breast cancer patients with 1 to 3 involved nodes. Future studies are needed to determine which HER-2 positive breast cancer patients benefit the most from PMRT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Abi Jaoude J, de Azambuja E, Makki M, et al. Post-Mastectomy Radiation Therapy in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients: Analysis of the HERA Trial. Int J Radiat Oncol Biol Phys. 2019. PMID: 31654782. doi:10.1016/j.ijrobp.2019.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。